SEC Form 4 · accession 0001104659-16-161328
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Y Chan
Officer — See Remarks
Period of report
Dec 6, 2016
Accepted (ET)
Dec 8, 2016 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Dec 6, 2016 | A | 75,000 | A | — | — | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one common share of the Issuer.
- F225% of the units will vest on December 6, 2017 and the remaining 75% of the units will vest on December 6, 2018, subject, in each case, with limited exceptions, to the Reporting Person's continued employment with the Issuer or any of its subsidiaries.
Remarks
President & Chief Accounting Officer of Aegerion Pharmaceuticals, Inc.